Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) Forecasted to Post Q2 2024 Earnings of ($0.58) Per Share

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) – Investment analysts at B. Riley issued their Q2 2024 EPS estimates for Actinium Pharmaceuticals in a report released on Wednesday, May 1st. B. Riley analyst Y. Zhi expects that the biotechnology company will earn ($0.58) per share for the quarter. The consensus estimate for Actinium Pharmaceuticals’ current full-year earnings is ($1.48) per share. B. Riley also issued estimates for Actinium Pharmaceuticals’ Q3 2024 earnings at ($0.53) EPS, Q4 2024 earnings at ($0.37) EPS, FY2024 earnings at ($1.49) EPS and FY2025 earnings at ($0.45) EPS.

A number of other brokerages have also issued reports on ATNM. Maxim Group boosted their target price on shares of Actinium Pharmaceuticals from $20.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, March 19th. Cantor Fitzgerald restated an “overweight” rating and issued a $21.00 target price on shares of Actinium Pharmaceuticals in a research note on Tuesday, April 30th. StockNews.com upgraded Actinium Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday. Finally, HC Wainwright reiterated a “buy” rating and issued a $50.00 target price on shares of Actinium Pharmaceuticals in a report on Monday, April 29th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $25.72.

Actinium Pharmaceuticals Stock Performance

NYSEAMERICAN ATNM opened at $8.79 on Monday. Actinium Pharmaceuticals has a fifty-two week low of $4.00 and a fifty-two week high of $9.86. The company has a market cap of $261.62 million, a PE ratio of -5.14 and a beta of 0.08.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last announced its earnings results on Friday, March 29th. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.21. The business had revenue of $0.08 million for the quarter.

Institutional Trading of Actinium Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Sanders Morris Harris LLC acquired a new position in shares of Actinium Pharmaceuticals in the first quarter worth about $78,000. Creative Financial Designs Inc. ADV boosted its position in Actinium Pharmaceuticals by 19.1% during the fourth quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company’s stock worth $101,000 after purchasing an additional 3,175 shares in the last quarter. Finally, Brandywine Global Investment Management LLC purchased a new stake in shares of Actinium Pharmaceuticals in the third quarter valued at approximately $1,033,000. 27.50% of the stock is owned by institutional investors and hedge funds.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.